Download as PDF
PreveCeutical™ Medical Inc. Announces Preliminary Results from Phase One of its Venom Re-Engineering Project
FOR IMMEDIATE RELEASE…Vancouver, British Columbia: PreveCeutical™ Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV) (FSE: 18H) announces encouraging results from the Research and Development (“R&D”) project consisting of isolating and identifying peptides and proteins from Caribbean Blue Scorpion venom.
The R&D program consists of three distinct phases. Currently underway, phase one involves one-dimensional gel electrophoresis (“1DE”) to first identify scorpion venom-based peptides/proteins based on their size (KDa). The results from the 1DE studies confirm the presence of peptide/protein bands at around 55KDa and 45KDa, with a highly prominent band observed at ≤10KDa.
Further separation of constituent peptides/proteins underlying the ≤10KDa band is planned next, and once separation parameters are optimized, two-dimensional gel electrophoresis (“2DE”) will be employed whereby separation by size (KDa) and isoelectric point (pH) will follow. 2DE is a universally-accepted technique for enabling efficient separation of potentially thousands of peptides/proteins from complex samples, which can then be quantified and sequenced.
Using the peptide sequence data, PreveCeutical’s scientists will use a proprietary chemistry to generate Nature Identical™ peptides, consisting of a library of modified peptide analogues, which will then be tested in disease models. The identified active peptides will then be progressed through the pre-clinical screening process, toward achieving the goal of an Investigational New Drug (“IND”) application through established pharmaceutical regulatory processes.
About PreveCeutical Medical Inc.
PreveCeutical Medical Inc. (CSE: PREV) (FSE: 18H) is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
The Company currently has one product available for sale, the CELLB9® Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. The active potentiated ingredients in the Blue Scorpion venom appear to support health at a deep cellular level, having been used for many years and in over 40 countries. The solution is colourless and odourless and can be administered orally.
For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
On Behalf of the Board of Directors
Stephen Van Deventer
Chairman & CEO
For further information, please contact:
Deanna Kress
Director of Corporate Communications & Investor Relations
+1-778-999-6063
deanna@preveceutical.com
Forward-Looking Statements:
This news release includes certain statements that constitute “forward-looking information” within the meaning of applicable Canadian securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. Statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future. Often, but not always, forward-looking statements can be identified by words such as “pro forma”, “plans”, “expects”, “may”, “should”, “budget”, “schedules”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Such forward-looking statements include, among others, statements as to the proposed first phase of the Company's venom re-engineering project, business plans of the Company regarding the foregoing, the timing of future activities and the prospects of their success for the Company, and the Company’s ability and success in executing its proposed business plans, including a successful IND application. Actual results could differ from those projected in any forward-looking statements due to numerous factors including risks and uncertainties relating to the inability of the Company, to, among other things, complete the proposed research project as planned or the inability of the Company to obtain any required governmental approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, or financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry, may also adversely affect the future results or performance of the Company, including the completion of the proposed research programs. There is no guarantee that the research programs will be successful or that their results can be commercialised by the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.